PRESS RELEASE published on 11/09/2023 at 14:30, 10 months 19 days ago Breast Cancer Related Results of Groundbreaking Napo Pharmaceuticals (a Jaguar Health Family Company) Supported Study on Quality of Life for Cancer Patients and Survivors Accepted for Presentation at the December 2023 San Antonio Breast Cancer Symposium
PRESS RELEASE published on 11/08/2023 at 16:25, 10 months 20 days ago Jaguar Health Receives Additional 180-day Grace Period to Regain Compliance with Nasdaq's Bid Price Rule
PRESS RELEASE published on 11/08/2023 at 14:30, 10 months 20 days ago Jaguar Health to Hold Investor Webcast Tuesday, November 14th at 8:30 AM Eastern Regarding Q3 2023 Financials & Corporate Updates
PRESS RELEASE published on 11/07/2023 at 14:30, 10 months 21 days ago REMINDER: Jaguar Health to Host Virtual Educational Webinar on Rare Intestinal Failure Diseases with Leading Gastroenterologists and Nutrition Experts November 8th from 1:00 PM to 2:30 PM EST
PRESS RELEASE published on 11/02/2023 at 13:30, 10 months 26 days ago Jaguar Health Enters Exclusive Crofelemer Revenue Sharing License and Commercialization Agreement with Quadri Pharmaceuticals Store for Rare Intestinal Failure Diseases in Middle East Markets
PRESS RELEASE published on 11/01/2023 at 13:30, 10 months 27 days ago Issuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
PRESS RELEASE published on 10/30/2023 at 13:30, 10 months 29 days ago Magdalena Biosciences, a Joint Venture between Jaguar Health and Filament Health, Receives Second Tranche of Funding from One Small Planet
PRESS RELEASE published on 10/26/2023 at 14:30, 11 months 2 days ago Jaguar Health to Present November 1st at Emerging Growth Conference
PRESS RELEASE published on 10/23/2023 at 14:30, 11 months 5 days ago Magdalena Biosciences Initiates Preclinical Study to Evaluate Plant Extracts to Treat Depression, Anxiety, ADHD and Other Mental Health Indications
PRESS RELEASE published on 10/19/2023 at 14:30, 11 months 9 days ago Independent Study Conducted at Boston Children's Hospital, Harvard Medical School, Shows Potential Utility of Jaguar Health's Crofelemer for Treatment of MVID, a Rare Childhood Disease
Published on 09/28/2024 at 02:06, 1 day 1 hour ago Global Education Communities Corp. Reports Second Tranche Closing of Non-Brokered Private Placement
Published on 09/28/2024 at 02:00, 1 day 1 hour ago bettermoo(d)’s Moodrink(TM) Featured in Banners of Well-Known Canadian Retailers
Published on 09/28/2024 at 00:10, 1 day 3 hours ago LQWD Technologies Announces Non-Brokered Private Placement Update
Published on 09/28/2024 at 14:01, 13 hours 26 minutes ago Turkiye Garanti Bankasi A.S.: Explanation on Subordinated Debt Securities to Qualified Investors
Published on 09/27/2024 at 22:30, 1 day 4 hours ago DREAM Pivotal Study Data Presented at the International Surgical Sleep Society 2024 Educational Update
Published on 09/27/2024 at 21:56, 1 day 5 hours ago EQS-Adhoc: FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz)
Published on 09/27/2024 at 18:50, 1 day 8 hours ago PETROFAC ANNOUNCES IN-PRINCIPLE AGREEMENT ON FINANCIAL RESTRUCTURE
Published on 09/27/2024 at 18:40, 1 day 8 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 09/27/2024 at 17:45, 1 day 9 hours ago NFL BIOSCIENCES: 2024 FIRST-HALF BUSINESS AND EARNINGS UPDATE
Published on 09/26/2024 at 18:00, 2 days 9 hours ago GUILLEMOT CORPORATION: Availability of the interim financial report to June 30, 2024
Published on 09/26/2024 at 18:00, 2 days 9 hours ago GUILLEMOT CORPORATION: 2024 CONSOLIDATED INTERIM RESULTS
Published on 09/26/2024 at 17:47, 2 days 9 hours ago imerys-26-September-2024-information-share-capital-and-voting-rights-as-of-31-August-2024